Stocktoria
Zai Lab Ltd ZLAB
Zai Lab Ltd (ZLAB) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $460.2M at a -38.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.33 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-07 | Citigroup | Buy (main) |
| 2026-05-08 | Citigroup | Buy (main) |
| 2026-03-18 | JP Morgan | Overweight (main) |
| 2026-02-27 | Cantor Fitzgerald | Overweight (main) |
| 2026-02-05 | JP Morgan | Overweight (main) |
| 2026-01-07 | UBS | Buy (init) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.514 |
| Retained earnings / assets | -2.242 |
| EBIT / assets | -0.196 |
| Equity / liabilities | 1.566 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ZLAB | Zai Lab Ltd | 3/9 | -3.61 | — | +15.3% |
| NATR | NATURES SUNSHINE PRODUCTS INC | 6/9 | 5.82 | 18.9 | +5.7% |
| TVTX | Travere Therapeutics, Inc. | 5/9 | -5.38 | — | +110.5% |
| BBIO | BridgeBio Pharma, Inc. | 1/9 | -14.22 | — | +126.3% |
| INVA | Innoviva, Inc. | 3/9 | 6.59 | — | +14.7% |
| ARDX | ARDELYX, INC. | 2/9 | -2.34 | — | +22.1% |
| ESPR | Esperion Therapeutics, Inc. | 3/9 | -8.63 | — | +21.3% |
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
FAQ
Is ZLAB financially healthy?
Zai Lab Ltd's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ZLAB pay a dividend?
No, Zai Lab Ltd does not currently pay a dividend.
How profitable is ZLAB?
In FY2025, Zai Lab Ltd had a net margin of -38.1% and a return on equity of -24.5%.
What is the analyst price target for ZLAB?
The average Wall-Street price target for Zai Lab Ltd is $32.18, about 26.3% above the recent price, from 12 analysts (consensus: strong buy).
Is ZLAB a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Zai Lab Ltd: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.